Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study

Osteoarthritis (OA) is characterized by the gradual loss of cartilage. Sprifermin, a recombinant FGF18, is being developed as a cartilage anabolic drug. PRO-C2 is a serum marker of type II collagen formation and low levels have been shown to be prognostic of radiographic progression. The aim of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Osteoarthritis and cartilage 2022-01, Vol.30 (1), p.92-99
Hauptverfasser:	Bay-Jensen, A.C., Manginelli, A.A., Karsdal, M., Luo, Y., He, Y., Michaelis, M., Guehring, H., Ladel, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biomarker Biomarkers - analysis Biomarkers - blood Cartilage Cartilage, Articular - drug effects Cartilage, Articular - pathology Collagen Type II - analysis Collagen Type II - blood Double-Blind Method Female Fibroblast Growth Factors - administration & dosage Fibroblast Growth Factors - pharmacology Fibroblast Growth Factors - therapeutic use Growth factor Humans Injections, Intra-Articular Male Middle Aged Organ Size Osteoarthritis Osteoarthritis - drug therapy Prediction Sprifermin Synovial Fluid - chemistry Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!